Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Malignant Lymphoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 118 articles:
HTML format



Single Articles


    May 2020
  1. NASTOUPIL LJ, Jain MD, Feng L, Spiegel JY, et al
    Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
    J Clin Oncol. 2020 May 13:JCO1902104. doi: 10.1200/JCO.19.02104.
    PubMed     Abstract available


    March 2020
  2. MORTON LM
    Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors.
    J Clin Oncol. 2020 Mar 31:JCO2000361. doi: 10.1200/JCO.20.00361.
    PubMed    


    February 2020
  3. SHREE T, Li Q, Glaser SL, Brunson A, et al
    Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2020 Feb 21:JCO1901937. doi: 10.1200/JCO.19.01937.
    PubMed     Abstract available


  4. JAFFE ES, Ashar BS, Clemens MW, Feldman AL, et al
    Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
    J Clin Oncol. 2020 Feb 11:JCO1902778. doi: 10.1200/JCO.19.02778.
    PubMed     Abstract available


  5. FATOBENE G, Rocha V, St Martin A, Hamadani M, et al
    Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.
    J Clin Oncol. 2020 Feb 7:JCO1902408. doi: 10.1200/JCO.19.02408.
    PubMed     Abstract available


    January 2020
  6. ADAMS HJA, Kwee TC
    Inability of Fluorodeoxyglucose Positron Emission Tomography to Detect Viable Hodgkin Lymphoma During and After Treatment.
    J Clin Oncol. 2020 Jan 30:JCO1902780. doi: 10.1200/JCO.19.02780.
    PubMed    


  7. BARTLETT NL
    Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle.
    J Clin Oncol. 2020 Jan 10:JCO1902816. doi: 10.1200/JCO.19.02816.
    PubMed     Abstract available


    December 2019
  8. SORIGUE M
    Immune Infiltration and the Potential for a Biology-Guided Approach to Follicular Lymphoma.
    J Clin Oncol. 2019 Dec 9:JCO1902398. doi: 10.1200/JCO.19.02398.
    PubMed    


  9. KLUIN-NELEMANS HC, Hoster E, Hermine O, Walewski J, et al
    Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    J Clin Oncol. 2019 Dec 5:JCO1901294. doi: 10.1200/JCO.19.01294.
    PubMed     Abstract available


    November 2019
  10. SHINGLETON JR, Dave SS
    Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Nov 26:JCO1902587. doi: 10.1200/JCO.19.02587.
    PubMed    


  11. SEHN LH, Herrera AF, Flowers CR, Kamdar MK, et al
    Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Nov 6:JCO1900172. doi: 10.1200/JCO.19.00172.
    PubMed     Abstract available


    October 2019
  12. EICHENAUER DA, Plutschow A, Fuchs M, Sasse S, et al
    Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.
    J Clin Oncol. 2019 Oct 18:JCO1900986. doi: 10.1200/JCO.19.00986.
    PubMed     Abstract available


  13. BORCHMANN S, Cirillo M, Goergen H, Meder L, et al
    Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma.
    J Clin Oncol. 2019 Oct 17:JCO1900985. doi: 10.1200/JCO.19.00985.
    PubMed     Abstract available


  14. ARMAND P, Rodig S, Melnichenko V, Thieblemont C, et al
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Oct 14:JCO1901389. doi: 10.1200/JCO.19.01389.
    PubMed     Abstract available


    September 2019
  15. KOBE C, Goergen H, Fuchs M, Muller H, et al
    Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2019 Sep 30:JCO1901761. doi: 10.1200/JCO.19.01761.
    PubMed    


  16. ADAMS HJA, Kwee TC
    Only a Small Proportion of Patients With Early-Stage Hodgkin Lymphoma May Potentially Benefit From Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment Escalation.
    J Clin Oncol. 2019 Sep 30:JCO1901491. doi: 10.1200/JCO.19.01491.
    PubMed    


  17. KAHN JM, Kelly KM, Pei Q, Bush R, et al
    Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study.
    J Clin Oncol. 2019 Sep 20:JCO1900812. doi: 10.1200/JCO.19.00812.
    PubMed     Abstract available


  18. FUCHS M, Goergen H, Kobe C, Kuhnert G, et al
    Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
    J Clin Oncol. 2019 Sep 10:JCO1900964. doi: 10.1200/JCO.19.00964.
    PubMed     Abstract available


  19. ROSENWALD A, Bens S, Advani R, Barrans S, et al
    Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
    J Clin Oncol. 2019 Sep 9:JCO1900743. doi: 10.1200/JCO.19.00743.
    PubMed     Abstract available


    August 2019
  20. TOBIN JWD, Keane C, Gunawardana J, Mollee P, et al
    Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
    J Clin Oncol. 2019 Aug 28:JCO1802365. doi: 10.1200/JCO.18.02365.
    PubMed     Abstract available


  21. ZINZANI PL, Santoro A, Gritti G, Brice P, et al
    Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
    J Clin Oncol. 2019 Aug 9:JCO1901492. doi: 10.1200/JCO.19.01492.
    PubMed     Abstract available


    July 2019
  22. BACHY E, Seymour JF, Feugier P, Offner F, et al
    Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
    J Clin Oncol. 2019 Jul 24:JCO1901073. doi: 10.1200/JCO.19.01073.
    PubMed     Abstract available


  23. EHRHARDT MJ, Chen Y, Sandlund JT, Bluhm EC, et al
    Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 8:JCO1900525. doi: 10.1200/JCO.19.00525.
    PubMed     Abstract available


    June 2019
  24. WANG Y, Farooq U, Link BK, Larson MC, et al
    Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
    J Clin Oncol. 2019 Jun 6:JCO1900014. doi: 10.1200/JCO.19.00014.
    PubMed     Abstract available


  25. LIN JK, Muffly LS, Spinner MA, Barnes JI, et al
    Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Jun 3:JCO1802079. doi: 10.1200/JCO.18.02079.
    PubMed     Abstract available


    May 2019
  26. RAMCHANDREN R, Domingo-Domenech E, Rueda A, Trneny M, et al
    Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
    J Clin Oncol. 2019 May 21:JCO1900315. doi: 10.1200/JCO.19.00315.
    PubMed     Abstract available


  27. BARRINGTON SF, Phillips EH, Counsell N, Hancock B, et al
    Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.
    J Clin Oncol. 2019 May 21:JCO1801799. doi: 10.1200/JCO.18.01799.
    PubMed     Abstract available


    April 2019
  28. NIE J, Wang C, Liu Y, Yang Q, et al
    Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    J Clin Oncol. 2019 Apr 30:JCO1802151. doi: 10.1200/JCO.18.02151.
    PubMed     Abstract available


  29. SIKIC BI, Lakhani N, Patnaik A, Shah SA, et al
    First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
    J Clin Oncol. 2019;37:946-953.
    PubMed     Abstract available


  30. LEONARD JP
    De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Apr 2:JCO1900445. doi: 10.1200/JCO.19.00445.
    PubMed    


  31. BARTLETT NL, Wilson WH, Jung SH, Hsi ED, et al
    Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
    J Clin Oncol. 2019 Apr 2:JCO1801994. doi: 10.1200/JCO.18.01994.
    PubMed     Abstract available


  32. HUNTINGTON SF, von Keudell G, Davidoff AJ, Gross CP, et al
    Reply to H.J.A. Adams et al.
    J Clin Oncol. 2019;37:853-854.
    PubMed    


    March 2019
  33. YOUNES A, Sehn LH, Johnson P, Zinzani PL, et al
    Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Mar 22:JCO1802403. doi: 10.1200/JCO.18.02403.
    PubMed     Abstract available


  34. BARR PM
    Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab.
    J Clin Oncol. 2019 Mar 22:JCO1900419. doi: 10.1200/JCO.19.00419.
    PubMed    


  35. LEONARD JP, Trneny M, Izutsu K, Fowler NH, et al
    AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2019 Mar 21:JCO1900010. doi: 10.1200/JCO.19.00010.
    PubMed     Abstract available


  36. SHAW AT, Solomon BJ, Besse B, Bauer TM, et al
    ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Mar 20:JCO1802236. doi: 10.1200/JCO.18.02236.
    PubMed     Abstract available


  37. KURTZ DM, Scherer F, Jin MC, Soo J, et al
    Reply to J. Wang et al.
    J Clin Oncol. 2019;37:755-757.
    PubMed    


  38. LOCKMER S, Ostenstad B, Hagberg H, Holte H, et al
    Reply to M. Sorigue et al.
    J Clin Oncol. 2019;37:759-760.
    PubMed    


    February 2019
  39. FLINN IW, van der Jagt R, Kahl B, Wood P, et al
    First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    J Clin Oncol. 2019 Feb 27:JCO1800605. doi: 10.1200/JCO.18.00605.
    PubMed     Abstract available


  40. FRUMAN DA
    Targeting PI3K-Gamma in Non-Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 27:JCO1900215. doi: 10.1200/JCO.19.00215.
    PubMed    


  41. HOUILLIER C, Taillandier L, Dureau S, Lamy T, et al
    Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
    J Clin Oncol. 2019 Feb 20:JCO1800306. doi: 10.1200/JCO.18.00306.
    PubMed     Abstract available


  42. SHI Q, Flowers CR
    Reply to H.J.A. Adams et al.
    J Clin Oncol. 2019;37:526-527.
    PubMed    


  43. WANG J, Dong R, Li K
    Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Feb 12:JCO1801385. doi: 10.1200/JCO.18.01385.
    PubMed    


  44. FLINN IW, Miller CB, Ardeshna KM, Tetreault S, et al
    DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 11:JCO1800915. doi: 10.1200/JCO.18.00915.
    PubMed     Abstract available


  45. ADAMS HJA, Kwee TC
    A 73% Price Reduction Does Not Indisputably Justify Routine Application of Brentuximab Vedotin as First-Line Treatment of Hodgkin Lymphoma.
    J Clin Oncol. 2019 Feb 11:JCO1801830. doi: 10.1200/JCO.18.01830.
    PubMed    


  46. SORIGUE M, Sancho JM
    Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma?
    J Clin Oncol. 2019 Feb 8:JCO1801761. doi: 10.1200/JCO.18.01761.
    PubMed    


  47. BICCLER JL, Glimelius I, Eloranta S, Smeland KB, et al
    Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.
    J Clin Oncol. 2019 Feb 6:JCO1801652. doi: 10.1200/JCO.18.01652.
    PubMed     Abstract available


  48. O'CONNOR OA, Ozcan M, Jacobsen ED, Roncero JM, et al
    Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2019 Feb 1:JCO1800899. doi: 10.1200/JCO.18.00899.
    PubMed     Abstract available


    January 2019
  49. MACMANUS M, Fisher R, McClure B, Seymour JF, et al
    Reply to M. Sorigue et al.
    J Clin Oncol. 2019;37:257-258.
    PubMed    


  50. COOK LB, Fuji S, Hermine O, Bazarbachi A, et al
    Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.
    J Clin Oncol. 2019 Jan 18:JCO1800501. doi: 10.1200/JCO.18.00501.
    PubMed     Abstract available


  51. GILLIGAN T
    Personalizing Medicine.
    J Clin Oncol. 2019;37:165-166.
    PubMed    


  52. ANSELL SM, Minnema MC, Johnson P, Timmerman JM, et al
    Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    J Clin Oncol. 2019 Jan 8:JCO1800766. doi: 10.1200/JCO.18.00766.
    PubMed     Abstract available


  53. GERSON JN, Handorf E, Villa D, Gerrie AS, et al
    Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
    J Clin Oncol. 2019 Jan 7:JCO1800690. doi: 10.1200/JCO.18.00690.
    PubMed     Abstract available


    December 2018
  54. ADAMS HJA, Kwee TC
    Standardized Definition of Progression-Free Survival in Diffuse Large B-Cell Lymphoma Is Urgently Needed.
    J Clin Oncol. 2018 Dec 28:JCO1801134. doi: 10.1200/JCO.18.01134.
    PubMed    


  55. JACOBSON CA
    CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2018 Dec 13:JCO1801457. doi: 10.1200/JCO.18.01457.
    PubMed     Abstract available


  56. SHA C, Barrans S, Cucco F, Bentley MA, et al
    Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
    J Clin Oncol. 2018 Dec 3:JCO1801314. doi: 10.1200/JCO.18.01314.
    PubMed     Abstract available


  57. CHAN WC
    Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801910. doi: 10.1200/JCO.18.01910.
    PubMed    


  58. ENNISHI D, Jiang A, Boyle M, Collinge B, et al
    Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801583. doi: 10.1200/JCO.18.01583.
    PubMed     Abstract available


    November 2018
  59. SARKOZY C, Maurer MJ, Link BK, Ghesquieres H, et al
    Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    J Clin Oncol. 2018 Nov 27:JCO1800400. doi: 10.1200/JCO.18.00400.
    PubMed     Abstract available


  60. SORIGUE M, Sancho JM
    Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography.
    J Clin Oncol. 2018 Nov 26:JCO1800854. doi: 10.1200/JCO.18.00854.
    PubMed    


    October 2018
  61. DAVIDS MS, von Keudell G, Portell CA, Cohen JB, et al
    Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
    J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359.
    PubMed    


  62. ALDERUCCIO JP, Zhao W, Desai A, Gallastegui N, et al
    Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.
    J Clin Oncol. 2018 Oct 12:JCO1800138. doi: 10.1200/JCO.18.00138.
    PubMed     Abstract available


  63. LOCKMER S, Ostenstad B, Hagberg H, Holte H, et al
    Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
    J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262.
    PubMed     Abstract available


  64. HUNTINGTON SF, von Keudell G, Davidoff AJ, Gross CP, et al
    Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.
    J Clin Oncol. 2018 Oct 4:JCO1800122. doi: 10.1200/JCO.18.00122.
    PubMed     Abstract available


    September 2018
  65. GISSELBRECHT C
    Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study?
    J Clin Oncol. 2018 Sep 17:JCO1800498. doi: 10.1200/JCO.18.00498.
    PubMed    


  66. ADAMS HJA, Kwee TC
    Unproven Clinical Value of Interim FDG-PET in Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 17:JCO1800323. doi: 10.1200/JCO.18.00323.
    PubMed    


  67. EVENS AM, Advani RH, Helenowski IB, Fanale M, et al
    Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 4:JCO2018790139. doi: 10.1200/JCO.2018.79.0139.
    PubMed     Abstract available


    August 2018
  68. YANG JC, Yahalom J
    Early-Stage Follicular Lymphoma: What Is the Preferred Treatment Strategy?
    J Clin Oncol. 2018 Aug 28:JCO2018793075. doi: 10.1200/JCO.2018.79.3075.
    PubMed    


  69. KURTZ DM, Scherer F, Jin MC, Soo J, et al
    Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Aug 20:JCO2018785246. doi: 10.1200/JCO.2018.78.5246.
    PubMed     Abstract available


    July 2018
  70. WEIBULL CE, Johansson ALV, Eloranta S, Smedby KE, et al
    Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.
    J Clin Oncol. 2018 Jul 25:JCO2018783514. doi: 10.1200/JCO.2018.78.3514.
    PubMed     Abstract available


  71. SASSE S, Goergen H, Plutschow A, Boll B, et al
    Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
    J Clin Oncol. 2018 Jul 10:JCO2018787192. doi: 10.1200/JCO.2018.78.7192.
    PubMed     Abstract available


  72. SHI Q, Schmitz N, Ou FS, Dixon JG, et al
    Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    J Clin Oncol. 2018 Jul 5:JCO2018779124. doi: 10.1200/JCO.2018.77.9124.
    PubMed     Abstract available


  73. MACMANUS M, Fisher R, Roos D, O'Brien P, et al
    Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
    J Clin Oncol. 2018 Jul 5:JCO2018779892. doi: 10.1200/JCO.2018.77.9892.
    PubMed     Abstract available


    June 2018
  74. FRIEDBERG JW
    Progress in Advanced-Stage Follicular Lymphoma.
    J Clin Oncol. 2018 Jun 1:JCO2018793083. doi: 10.1200/JCO.2018.79.3083.
    PubMed    


  75. HIDDEMANN W, Barbui AM, Canales MA, Cannell PK, et al
    Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    J Clin Oncol. 2018 Jun 1:JCO2017768960. doi: 10.1200/JCO.2017.76.8960.
    PubMed     Abstract available


    May 2018
  76. GOPAL AK, Schuster SJ, Fowler NH, Trotman J, et al
    Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
    J Clin Oncol. 2018 May 31:JCO2017768853. doi: 10.1200/JCO.2017.76.8853.
    PubMed     Abstract available


  77. MESGUICH C, Bouabdallah K, Milpied N, Hindie E, et al
    Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018786780. doi: 10.1200/JCO.2018.78.6780.
    PubMed    


  78. ADAMS HJA, Kwee TC
    Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018782524. doi: 10.1200/JCO.2018.78.2524.
    PubMed    


  79. MERRYMAN RW, LaCasce AS
    Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.
    J Clin Oncol. 2018 May 22:JCO2018789362. doi: 10.1200/JCO.2018.78.9362.
    PubMed    


  80. LETAI A
    Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2018 May 22:JCO2018782763. doi: 10.1200/JCO.2018.78.2763.
    PubMed    


  81. CAMIDGE DR, Kim DW, Tiseo M, Langer CJ, et al
    Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841.
    PubMed     Abstract available


    April 2018
  82. MAURER MJ, Ghesquieres H, Link BK, Jais JP, et al
    Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
    J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198.
    PubMed     Abstract available


    March 2018
  83. CHESON BD, Chua N, Mayer J, Dueck G, et al
    Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    J Clin Oncol. 2018 Mar 27:JCO2017763656. doi: 10.1200/JCO.2017.76.3656.
    PubMed     Abstract available


  84. ARMAND P, Engert A, Younes A, Fanale M, et al
    Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    J Clin Oncol. 2018 Mar 27:JCO2017760793. doi: 10.1200/JCO.2017.76.0793.
    PubMed     Abstract available


    February 2018
  85. ROEMER MGM, Redd RA, Cader FZ, Pak CJ, et al
    Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    J Clin Oncol. 2018 Feb 2:JCO2017773994. doi: 10.1200/JCO.2017.77.3994.
    PubMed     Abstract available


    January 2018
  86. GALLAMINI A, Tarella C, Viviani S, Rossi A, et al
    Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607
    J Clin Oncol. 2018 Jan 23:JCO2017752543. doi: 10.1200/JCO.2017.75.2543.
    PubMed     Abstract available


  87. SHADMAN M, Li H, Rimsza L, Leonard JP, et al
    Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
    J Clin Oncol. 2018 Jan 22:JCO2017745083. doi: 10.1200/JCO.2017.74.5083.
    PubMed     Abstract available


  88. BOLLARD CM, Tripic T, Cruz CR, Dotti G, et al
    Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
    J Clin Oncol. 2018 Jan 9:JCO2017743179. doi: 10.1200/JCO.2017.74.3179.
    PubMed     Abstract available


    November 2017
  89. LUMINARI S, Ferrari A, Manni M, Dondi A, et al
    Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    J Clin Oncol. 2017 Nov 2:JCO2017741652. doi: 10.1200/JCO.2017.74.1652.
    PubMed     Abstract available


    October 2017
  90. MAURER MJ, Ellin F, Srour L, Jerkeman M, et al
    International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2017 Oct 26:JCO2017738195. doi: 10.1200/JCO.2017.73.8195.
    PubMed     Abstract available


  91. DREYLING M, Santoro A, Mollica L, Leppa S, et al
    Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2017 Oct 4:JCO2017754648. doi: 10.1200/JCO.2017.75.4648.
    PubMed     Abstract available


    September 2017
  92. HERRERA AF, Armand P
    Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
    J Clin Oncol. 2017 Sep 21:JCO2017745281. doi: 10.1200/JCO.2017.74.5281.
    PubMed     Abstract available


  93. SALZ T, Zabor EC, de Nully Brown P, Dalton SO, et al
    Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2017 Sep 18:JCO2017724211. doi: 10.1200/JCO.2017.72.4211.
    PubMed     Abstract available


  94. CHAN FC, Mottok A, Gerrie AS, Power M, et al
    Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.
    J Clin Oncol. 2017 Sep 12:JCO2017727925. doi: 10.1200/JCO.2017.72.7925.
    PubMed     Abstract available


  95. LEONARD JP, Kolibaba KS, Reeves JA, Tulpule A, et al
    Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Sep 1:JCO2017732784. doi: 10.1200/JCO.2017.73.2784.
    PubMed     Abstract available


    August 2017
  96. MARTINEZ C, Gayoso J, Canals C, Finel H, et al
    Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and
    J Clin Oncol. 2017 Aug 28:JCO2017726869. doi: 10.1200/JCO.2017.72.6869.
    PubMed     Abstract available


  97. VITOLO U, Trneny M, Belada D, Burke JM, et al
    Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Aug 10:JCO2017733402. doi: 10.1200/JCO.2017.73.3402.
    PubMed     Abstract available


  98. MOSSE YP, Voss SD, Lim MS, Rolland D, et al
    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    J Clin Oncol. 2017 Aug 8:JCO2017734830. doi: 10.1200/JCO.2017.73.4830.
    PubMed     Abstract available


    July 2017
  99. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    PubMed     Abstract available


  100. VARGO JA, Ling DC, Beriwal S
    Treatment of Early-Stage Hodgkin Lymphoma: Are We Just Shifting Morbidities?
    J Clin Oncol. 2017 Jul 6:JCO2017733568. doi: 10.1200/JCO.2017.73.3568.
    PubMed    


  101. HINDIE E, Mesguich C, Zanotti-Fregonara P
    On the Role of Interim Fluorine-18-Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017738369. doi: 10.1200/JCO.2017.73.8369.
    PubMed    


  102. ADAMS HJA, Kwee TC
    Interim Fluorodeoxyglucose Positron Emission Tomography-Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017733816. doi: 10.1200/JCO.2017.73.3816.
    PubMed    


    June 2017
  103. LEONARD JP, Martin P, Roboz GJ
    Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
    J Clin Oncol. 2017 Jun 27:JCO2017726745. doi: 10.1200/JCO.2017.72.6745.
    PubMed     Abstract available


  104. GROMMES C, DeAngelis LM
    Primary CNS Lymphoma.
    J Clin Oncol. 2017 Jun 22:JCO2017727602. doi: 10.1200/JCO.2017.72.7602.
    PubMed     Abstract available


    May 2017
  105. STAIGER AM, Ziepert M, Horn H, Scott DW, et al
    Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    J Clin Oncol. 2017 May 19:JCO2016703660. doi: 10.1200/JCO.2016.70.3660.
    PubMed     Abstract available


  106. WITZIG TE
    Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
    J Clin Oncol. 2017 May 17:JCO2017732578. doi: 10.1200/JCO.2017.73.2578.
    PubMed    


  107. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed    


  108. LANDSBURG DJ, Falkiewicz MK, Maly J, Blum KA, et al
    Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
    J Clin Oncol. 2017 May 5:JCO2017722157. doi: 10.1200/JCO.2017.72.2157.
    PubMed     Abstract available


  109. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Abstract available


  110. LAURENT C, Baron M, Amara N, Haioun C, et al
    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol. 2017 May 1:JCO2016712083. doi: 10.1200/JCO.2016.71.2083.
    PubMed     Abstract available


    April 2017
  111. KAMDAR MK, Smith SM
    Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
    J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
    PubMed     Abstract available


  112. CHEN R, Zinzani PL, Fanale MA, Armand P, et al
    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
    J Clin Oncol. 2017 Apr 25:JCO2016721316. doi: 10.1200/JCO.2016.72.1316.
    PubMed     Abstract available


  113. THIEBLEMONT C, Tilly H, Gomes da Silva M, Casasnovas RO, et al
    Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    J Clin Oncol. 2017 Apr 20:JCO2017726984. doi: 10.1200/JCO.2017.72.6984.
    PubMed     Abstract available


  114. SASSE S, Brockelmann PJ, Goergen H, Plutschow A, et al
    Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    J Clin Oncol. 2017 Apr 18:JCO2016709410. doi: 10.1200/JCO.2016.70.9410.
    PubMed     Abstract available


  115. MEYER RM
    Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty.
    J Clin Oncol. 2017 Apr 3:JCO2017722611. doi: 10.1200/JCO.2017.72.2611.
    PubMed    


    March 2017
  116. ZUCCA E, Conconi A, Martinelli G, Bouabdallah R, et al
    Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
    J Clin Oncol. 2017 Mar 29:JCO2016706994. doi: 10.1200/JCO.2016.70.6994.
    PubMed     Abstract available


  117. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
    Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
    PubMed     Abstract available


    January 2017
  118. HERRERA AF, Mei M, Low L, Kim HT, et al
    Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    J Clin Oncol. 2017;35:24-31.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: